[go: up one dir, main page]

PL406228A1 - Laccase enzyme isolated from Cerrena unicolor fungus to be applied in treatments of blood neoplastic diseases - Google Patents

Laccase enzyme isolated from Cerrena unicolor fungus to be applied in treatments of blood neoplastic diseases

Info

Publication number
PL406228A1
PL406228A1 PL406228A PL40622813A PL406228A1 PL 406228 A1 PL406228 A1 PL 406228A1 PL 406228 A PL406228 A PL 406228A PL 40622813 A PL40622813 A PL 40622813A PL 406228 A1 PL406228 A1 PL 406228A1
Authority
PL
Poland
Prior art keywords
fungus
treatments
neoplastic diseases
laccase enzyme
enzyme isolated
Prior art date
Application number
PL406228A
Other languages
Polish (pl)
Other versions
PL225934B1 (en
Inventor
Magdalena Jaszek
Anna Matuszewska
Monika Osińska-Jaroszuk
Grzegorz Janusz
Justyna Sulej
Dawid Stefaniuk
Krzysztof Giannopoulos
Marta Karp
Original Assignee
Uniwersytet Marii Curie-Skłodowskiej
Uniwersytet Medyczny W Lublinie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Marii Curie-Skłodowskiej, Uniwersytet Medyczny W Lublinie filed Critical Uniwersytet Marii Curie-Skłodowskiej
Priority to PL406228A priority Critical patent/PL225934B1/en
Publication of PL406228A1 publication Critical patent/PL406228A1/en
Publication of PL225934B1 publication Critical patent/PL225934B1/en

Links

Landscapes

  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Przedmiotem wynalazku jest enzym lakaza wyizolowany z grzyba Cerrena unicolor, do zastosowania w leczeniu chorób nowotworowych krwi.The subject of the invention is the laccase enzyme isolated from the fungus Cerrena unicolor, for use in the treatment of blood cancers.

PL406228A 2013-11-25 2013-11-25 Laccase enzyme isolated from Cerrena unicolor fungus to be applied in treatments of blood neoplastic diseases PL225934B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL406228A PL225934B1 (en) 2013-11-25 2013-11-25 Laccase enzyme isolated from Cerrena unicolor fungus to be applied in treatments of blood neoplastic diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL406228A PL225934B1 (en) 2013-11-25 2013-11-25 Laccase enzyme isolated from Cerrena unicolor fungus to be applied in treatments of blood neoplastic diseases

Publications (2)

Publication Number Publication Date
PL406228A1 true PL406228A1 (en) 2015-06-08
PL225934B1 PL225934B1 (en) 2017-06-30

Family

ID=53269063

Family Applications (1)

Application Number Title Priority Date Filing Date
PL406228A PL225934B1 (en) 2013-11-25 2013-11-25 Laccase enzyme isolated from Cerrena unicolor fungus to be applied in treatments of blood neoplastic diseases

Country Status (1)

Country Link
PL (1) PL225934B1 (en)

Also Published As

Publication number Publication date
PL225934B1 (en) 2017-06-30

Similar Documents

Publication Publication Date Title
JOP20200192A1 (en) TIGIT . antibodies
SA519401522B1 (en) LAG-3 antibodies and combinations
CL2015002807A1 (en) Combination therapy
EA201690206A1 (en) THERAPEUTICALLY ACTIVE COMPOUNDS AND METHODS OF THEIR APPLICATION
EA201991214A1 (en) ANTIBODIES AGAINST PD-1 AND THEIR COMPOSITION
MX2018006831A (en) Methods of treatment of malignancies.
CA2919397C (en) Aryl ethers as hif-2.alpha. inhibitors for the treatment of cancer
EA201400178A1 (en) BREAST CANCER TREATMENT
TR201808169T3 (en) Recombinant probiotic bacteria.
SV2017005355A (en) CARRIER-ANTIBODY COMPOSITIONS AND METHODS TO PERFORM AND USE THEM
MX373789B (en) PYRIDINYL QUINOLINONE DERIVATIVES AS MUTANT ISOCITRATE DEHYDROGENASE INHIBITORS (MT-IDH).
CL2016001082A1 (en) Process for the synthesis of an indolamine 2,3-dioxygenase inhibitor
MX373103B (en) CYCLOPROPYLAMINES AS INHIBITORS OF LYSINE-SPECIFIC DEMETHYLASE 1 (LSD1).
EA201290901A1 (en) PHYTOCANNABINOIDS FOR THE TREATMENT OF MALIGNANT TUMOR
BR112015023797A2 (en) dual specificity binding proteins directed against il-1b and / or il-17
EA201890961A1 (en) COMBINED THERAPY FOR THE TREATMENT OF MALIGNANT NORROFORMATION
GEAP202114132A (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
EA201691824A1 (en) ANTIBODIES AGAINST EGFRVIII AND THEIR APPLICATIONS
EA201591801A1 (en) DRUG ANTIBODIES
MX2021013837A (en) APPROACH OF COMBINATION IMMUNOTHERAPIES FOR THE TREATMENT OF CANCER.
EA201790737A1 (en) COMBINED THERAPY
EA201500314A1 (en) DOSAGE FORMS OF ENZALUTAMIDE
MX2012009030A (en) IDENTIFICATION OF LKB1 MUTATION AS A PREDICTIVE BIOMARCATOR FOR SENSITIVITY TO TOR CINASA INHIBITORS.
MX377729B (en) Methods of treating melanoma
WO2015009726A3 (en) Medical uses of cd38 agonists